Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Merck
Scientific Title
A Multicenter, Open-label, Phase 2 Trial to Assess the Efficacy and Safety of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Melanoma Previously Exposed to an Anti-PD-1/L1 Agent